Onco Wiki / Droga

Doxazosin

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDDRUG-DOXAZOSIN
TipoFármaco
Alegais
Cardurabloqueador seletivo alfa-1Доксазозин
Estadoreviewed 2026-07-11 | pending_clinical_signoff
DoençasDIS-PHEOCHROMOCYTOMA
FontesSRC-ENDOCRINE-SOCIETY-PPGL-2014 SRC-NCCN-NET-2025

Fatos sobre as drogas

ClasseAntagã seletivo dos receptores adrenérgicos alfa-1 competitivo
MecanismoSelectively and reversibly blocks post-synaptic alpha-1 adrenergic receptors, reducing catecholamine-mediated peripheral vasoconstriction with less reflex tachycardia than non-selective irreversible agents (phenoxybenzamine) because alpha-2 presynaptic auto-inhibition of norepinephrine release is preserved. Used as an alternative preoperative alpha-blocker in pheochromocytoma / paraganglioma (PPGL) where mandatory preoperative alpha-blockade is required before surgery to prevent intraoperative hypertensive crisis (Endocrine Society 2014 PPGL guideline).
Dose típicaStarting dose typically 1-2 mg PO once daily, titrated upward every few days as tolerated toward blood-pressure normalization and symptom control ahead of PPGL surgery, per Endocrine Society 2014 PPGL guideline (SRC-ENDOCRINE-SOCIETY-PPGL-2014); usual ceiling in general antihypertensive use is 16 mg/day, though the dose actually required for adequate preoperative PPGL blockade is individualized by the treating team. Usual preoperative course runs roughly one to two weeks before surgery. Exact target BP/HR thresholds are NOT fixed numeric values in this stub -- see RF-PHEO-INADEQUATE-ALPHA-BLOCKADE for the hard sequencing gate this drug exists to satisfy.
Ucrânia registadaVerdade
NSZU reembolsadoFalso
Ucrânia verificada pela última vez2026-07-11

Notas

Selective alpha-1 blockade gives less reflex tachycardia and easier general availability than phenoxybenzamine (DRUG-PHENOXYBENZAMINE), making doxazosin a commonly used practical alternative for mandatory preoperative PPGL alpha-blockade; choice between the two is per local practice/availability, not modelled as a KB-level preference. STUB pending clinical co-lead signoff (CHARTER §6.1, dev-mode-exempted).

Usado por

Fármaco

Esquema terapêutico